Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Isambert

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 30, 2016
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)T Valentin, A Le Cesne, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)E Bompas, A Le Cesne, E Tresch-Bruneel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2008
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma GroupA Italiano, N Penel, Y-M Robin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trialL Belin, M Kamal, C Mauborgne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survivalA Italiano, M Toulmonde, A Cioffi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 11, 2014
Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma groupA T Falk, L Moureau-Zabotto, M Ouali, et al.
Presse Medicale (Paris, France : 1983)|February 25, 2000
[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer]B Cutuli, M Janvier, A de la Rochefordière, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2014
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trialA Adenis, J-Y Blay, B Bui-Nguyen, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 30, 2016
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)T Valentin, A Le Cesne, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 24, 2015
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)E Bompas, A Le Cesne, E Tresch-Bruneel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2008
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma GroupA Italiano, N Penel, Y-M Robin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trialL Belin, M Kamal, C Mauborgne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survivalA Italiano, M Toulmonde, A Cioffi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|October 11, 2014
Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma groupA T Falk, L Moureau-Zabotto, M Ouali, et al.
Presse Medicale (Paris, France : 1983)|February 25, 2000
[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer]B Cutuli, M Janvier, A de la Rochefordière, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2014
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trialA Adenis, J-Y Blay, B Bui-Nguyen, et al.
ESMO Open|July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgeryP Pautier, A Floquet, C Chevreau, et al.
Pageof 6